Goldman Sachs Takes 5.1% Passive Stake in GeneDx Holdings
Ticker: GSCE · Form: SC 13G · Filed: Feb 9, 2024 · CIK: 886982
| Field | Detail |
|---|---|
| Company | Goldman Sachs Group INC (GSCE) |
| Form Type | SC 13G |
| Filed Date | Feb 9, 2024 |
| Risk Level | low |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, passive-investment, health-services, SC-13G
TL;DR
**Goldman Sachs just bought 5.1% of GeneDx, signaling a big institutional bet on the health services company.**
AI Summary
Goldman Sachs Group Inc. has disclosed a significant passive ownership stake in GeneDx Holdings Corp., a health services company. As of December 29, 2023, Goldman Sachs holds 1,999,999 shares of GeneDx's Class A common stock, representing 5.1% of the company. This matters to investors because it signals that a major financial institution sees value in GeneDx, potentially boosting investor confidence and indicating a positive outlook for the stock.
Why It Matters
A large institutional investor like Goldman Sachs taking a significant stake can be seen as a vote of confidence, potentially attracting more investors and influencing the stock price positively.
Risk Assessment
Risk Level: low — This filing indicates a passive investment by a major institution, which generally reduces perceived risk for the underlying stock.
Analyst Insight
A smart investor would view this as a positive signal, potentially indicating institutional confidence in GeneDx's future, and might consider further research into GeneDx's fundamentals and market position.
Key Numbers
- 1,999,999 — Shares Owned (Number of Class A common stock shares of GeneDx Holdings Corp. held by Goldman Sachs Group Inc.)
- 5.1% — Ownership Percentage (Percentage of GeneDx Holdings Corp.'s Class A common stock owned by Goldman Sachs Group Inc.)
- December 29, 2023 — Event Date (The date that triggered the requirement for Goldman Sachs Group Inc. to file this Schedule 13G.)
Key Players & Entities
- Goldman Sachs Group Inc. (company) — filer and institutional investor
- GeneDx Holdings Corp. (company) — subject company, health services
- 1,999,999 (dollar_amount) — number of shares of Class A common stock owned by Goldman Sachs
- 5.1% (dollar_amount) — percentage of Class A common stock owned by Goldman Sachs
- December 29, 2023 (person) — date of event requiring the filing
Forward-Looking Statements
- GeneDx Holdings Corp. stock price may see increased investor interest due to Goldman Sachs's stake. (GeneDx Holdings Corp.) — medium confidence, target: Q2 2024
FAQ
What is the specific type of security Goldman Sachs Group Inc. acquired in GeneDx Holdings Corp.?
Goldman Sachs Group Inc. acquired Class A common stock, par value $0.0001 per share, of GeneDx Holdings Corp.
What was the date of the event that required Goldman Sachs Group Inc. to file this Schedule 13G?
The date of the event which required the filing of this statement was December 29, 2023.
Under which specific rule was this Schedule 13G filed by Goldman Sachs Group Inc.?
This Schedule 13G was filed under Rule 13d-1(b).
What is the CUSIP number for the Class A common stock of GeneDx Holdings Corp.?
The CUSIP number for the Class A common stock of GeneDx Holdings Corp. is 81663L200.
What was GeneDx Holdings Corp.'s former name before its name change on July 21, 2021?
Before its name change on July 21, 2021, GeneDx Holdings Corp. was formerly known as Sema4 Holdings Corp.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on February 9, 2024 by December 29, 2023 regarding GOLDMAN SACHS GROUP INC (GSCE).